A cannabis-derived compound reduced HIV drug-induced nerve pain in mice through CB2 receptors | Research

The takeaway

Beta-caryophyllene, a CB2-selective phytocannabinoid found in cannabis, prevented and reduced nerve pain caused by the HIV drug zalcitabine in mice without activating the psychoactive CB1 receptor.

HIV researchers, pain management specialists, and anyone interested in non-psychoactive cannabinoid therapeutics.

CB2-specific, no psychoactive effects

What the researchers found

Beta-caryophyllene (BCP) prevented the development of mechanical allodynia when co-administered with the NRTI zalcitabine and attenuated established pain through CB2 receptor activation. A CB2 antagonist (AM 630) blocked the pain-relieving effect, while a CB1 antagonist (AM 251) did not, confirming the CB2-specific mechanism. BCP also reduced inflammatory cytokines in paw skin and brain.

Why it matters

HIV-associated neuropathic pain responds poorly to available drugs. While smoked cannabis has shown benefit in clinical trials, the psychoactive effects of CB1 activation limit its use. BCP offers a potential alternative that targets pain through CB2 without psychoactive side effects.

The numbers in context

5 days of zalcitabine treatment induced mechanical allodynia. BCP reduced cytokine transcripts (IL-1beta, TNF-alpha, IFN-gamma) in both paw skin and brain. AM 630 (CB2 antagonist) blocked BCP effects. AM 251 (CB1 antagonist) did not.

How the study worked

Controlled animal study using female BALB/c mice treated with zalcitabine (ddC) for 5 days to induce neuropathic pain. BCP, minocycline, or pentoxifylline were co-administered. CB1 and CB2 receptor antagonists were used to determine mechanism. Cytokine transcripts and Erk1/2 phosphorylation were measured.

What this study cannot tell us

Mouse model of neuropathic pain may not fully represent the human condition. Only female mice were used. The NRTI tested (zalcitabine) is no longer commonly used in HIV treatment. Doses may not translate directly to humans.

How to read the evidence

Rated preliminary because this is an animal study using a single NRTI in one mouse strain.

When this study was published

Published in 2019. The tested NRTI (zalcitabine) is largely obsolete, but the CB2 pain mechanism may apply to other causes of neuropathy.

The bigger picture

Beta-caryophyllene is found in many plants beyond cannabis, including black pepper and cloves. If it can address neuropathic pain through CB2 without CB1-related side effects, it could offer a non-psychoactive cannabinoid-based treatment option for HIV patients.

Questions still open

Would BCP work for neuropathic pain caused by currently used HIV medications? Does the anti-inflammatory mechanism translate to human nerve tissue? What dose would be needed for clinical efficacy?

Common questions

What is beta-caryophyllene?

It is a terpene found in cannabis, black pepper, cloves, and other plants. It selectively activates CB2 cannabinoid receptors without the psychoactive effects associated with CB1 activation.

Could this help with other types of nerve pain?

Potentially. The CB2-mediated anti-inflammatory mechanism could apply to other neuropathic pain conditions, but this study only tested one specific cause (NRTI-induced neuropathy).

Read the original research

β-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain.

Molecules (Basel, Switzerland), 25(1)

View on PubMed ↗Publisher’s paper ↗

Citation

Aly, Esraa; Khajah, Maitham A; Masocha, Willias. (2019). β-Caryophyllene, a CB2-Receptor-Selective Phytocannabinoid, Suppresses Mechanical Allodynia in a Mouse Model of Antiretroviral-Induced Neuropathic Pain.. Molecules (Basel, Switzerland), 25(1). https://doi.org/10.3390/molecules25010106